BenevolentAI | Investor Conference Presentation Deck | 17 slides

BenevolentAI · 2022-11
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 1
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

3
coverage by narrative range · generated from this deck JSON

Slide inventory

17
every slide · same image gating as the playbook
01
Slide 1
front_matter
Open slide detailBeat · Problem (Identify pain)
02
front_matter
Open slide detailBeat · Problem (Identify pain)
03
front_matter
Open slide detailBeat · Problem (Identify pain)
04
front_matter
Open slide detailBeat · Problem (Identify pain)
05
summarize
Open slide detailBeat · Agitate (Make it worse)Loop · Cost Of Inaction
06
The slide uses a split-screen approach to contrast pre-clinical efficiency with clinical efficacy improvements.quantify_opportunity
Open slide detailBeat · Agitate (Make it worse)Loop · Cost Of Inaction
07
The slide uses a process flow diagram to illustrate the company's core technology stack.present_framework
Open slide detailBeat · Agitate (Make it worse)Loop · Cost Of Inaction
08
Industry benchmarks based on Paul et al Nat Rev Drug Discov 2010.compare_peers
Open slide detailBeat · Agitate (Make it worse)Loop · Cost Of Inaction
09
The chart highlights BenevolentAI's projected productivity (2023-2031) against established industry players.compare_peers
Open slide detailBeat · Solution (Provide relief)Loop · Quick Win Big Bet
10
The slide uses a circular process diagram for the platform and a branching flow for the business model (A, B, C, D).present_solution
Open slide detailBeat · Solution (Provide relief)Loop · Quick Win Big Bet
11
The chart uses a timeline-like progression (Target ID to Phase III) to visualize drug development stages.present_framework
Open slide detailBeat · Solution (Provide relief)Loop · Quick Win Big Bet
12
The slide uses a split-layout: left side defines the disease burden and market opportunity, right side defines the drug mechanism and target patient population.frame_problem
Open slide detailBeat · Solution (Provide relief)Loop · Quick Win Big Bet
13
The slide includes explicit caveats regarding the small sample size and short duration of the Phase Ib study.analyze_data
Open slide detailBeat · Solution (Provide relief)
14
The slide uses a split-layout with a summary of the collaboration on the left and a timeline/milestone tracker on the right.illustrate_case
Open slide detailBeat · Solution (Provide relief)
15
The slide uses a list-based structure to demonstrate the efficacy and speed of the AI platform, supported by external validation from The Lancet and Eli Lilly.summarize
Open slide detailBeat · Solution (Provide relief)
16
The slide uses a hub-and-spoke diagram to link the company to its five strategic capital allocation pillars.plan_implementation
Open slide detailBeat · Solution (Provide relief)
17
The slide uses a horizontal timeline structure to map specific drug programs (BEN-2293, BEN-8744, etc.) against time-based milestones.plan_implementation
Open slide detailBeat · Solution (Provide relief)